Physician profile
Dan H Evans
NPI 1730152273
$328.16
in general payments reported to CMS, 2019-2025
11 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.00 · 2021: $115 · 2022: $16.47 · 2024: $6.47 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $68.21 | 2020-2021 | |
| Novo Nordisk INC | $43.64 | 2025 | Ozempic |
| Amgen INC. | $37.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.25 | 2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $29.22 | 2025 | Ibsrela |
| Akebia Therapeutics INC | $27.86 | 2025 | Vafseo |
| Harmony Biosciences LLC | $27.15 | 2020 | |
| Welch Allyn | $24.38 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.66 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.47 | 2022 | |
| Cycle Pharmaceuticals INC | $6.47 | 2024 | Tiopronin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.